Developer docs
API playgroundTry for free, no card

Search company profiles

Snapdragon Chemistry

Full company profile

uuid0000saa

Namestring
Snapdragon Chemistry
Company typeenum
Private
Founded yearint
2014
Descriptiontext

Snapdragon Chemistry is a Waltham, Massachusetts-based chemistry technology company founded in 2014, operating as a subsidiary of Cambrex. The company focuses on developing practical manufacturing solutions for challenging chemical transformations, positioning itself in the pharmaceutical process chemistry and contract development space. Its core capability centers on synthetic chemistry expertise applied to pharmaceutical discovery and manufacturing, with the company maintaining a 51–100 employee footprint and an executive team led by CEO Matthew Bio, alongside a CSO (Eric Fang) and COO (Rick Lifsitz), with co-founder Sera Hwang among the founding team.

The company's documented external-facing product is the annual Snapdragon Prize for Innovation in Chemistry Technology, established in 2024 with a $50,000 unrestricted research grant awarded to leading academic researchers in synthetic chemistry whose work has potential to impact pharmaceutical discovery and manufacturing. The 2025 prize was awarded to Dr. Song Lin of Cornell University for work in electrosynthetic chemistry. Beyond the prize, the company has secured non-dilutive funding from DARPA ($1.5M, 2021), the National Science Foundation (~$225K, 2016), and the Massachusetts Life Sciences Center ($200K, 2017), indicating participation in government and translational research programs.

Business model specifics — pricing, customer mix, contract structure, and revenue mechanics — are not disclosed in available sources. Given the Cambrex parent, the implied model is likely a B2B services model serving pharmaceutical clients through Cambrex's broader commercial infrastructure, with Snapdragon functioning as a specialized process chemistry and innovation unit. Customer logos, segment composition, technology stack, and pricing are not publicly disclosed, representing a material evidence gap for any investor diligence.

Short descriptiontext

Snapdragon Chemistry is a Waltham, MA-based subsidiary of Cambrex that develops practical manufacturing solutions for challenging chemical transformations, serving the pharmaceutical discovery and manufacturing sector through specialized synthetic chemistry expertise.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersWaltham, United States
HQ citystring
Waltham
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Keyword5 values
contract pharmaceutical chemistry, custom synthesis services, chemical process development, API manufacturing solutions, synthetic chemistry research
Industry3 codes
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code2 codes
  • Pharmaceutical and Medicine Manufacturing32541
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Medicinal Chemicals & Botanical Products2833
Product category
Contract Pharmaceutical Chemistry Services
Cost components4 values
Personnel, Operations, Technology or R&D, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Snapdragon Chemistry develops practical manufacturing solutions for challenging chemical transformations, providing custom synthesis and process development services to pharmaceutical and biotech clients. The company focuses on solving difficult synthetic chemistry problems to enable scalable production of active pharmaceutical ingredients.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

Snapdragon Chemistry, a subsidiary of Cambrex, operates as a chemistry technology company. Based on the source data, the company appears to focus on pharmaceutical chemistry development and manufacturing, with its primary documented offering being the Snapdragon Prize for Innovation in Chemistry Technology—an annual award program established in 2024 that recognizes academic researchers in synthetic chemistry whose work advances pharmaceutical discovery and manufacturing.

Product and service1 record
1Custom Synthesis Services
Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2026-02-19
Description

Snapdragon Chemistry is a subsidiary of Cambrex. Cambrex announced the 2025 Snapdragon Prize for Innovation in Chemistry Technology awarded to Dr. Song Lin from Cornell University. The prize recognizes academic research in synthetic chemistry that impacts pharmaceutical discovery and manufacturing.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight2 records

Each record includes

Type, Description

Peers10 records
1Asymchem
TypeDirect peer
Description

China-headquartered CDMO with deep capabilities in complex small-molecule chemistry, chiral synthesis, and API manufacturing — directly comparable to Snapdragon's challenging-transformations focus, with a much larger operational footprint.

TypeDirect peer
Description

Privately-held specialist CDMO known for complex API development, particle engineering, and challenging chemistry — closely aligned with Snapdragon's positioning in difficult small-molecule manufacturing.

TypeDirect peer
Description

Publicly-traded enzyme engineering company that develops biocatalytic and synthetic routes for pharmaceutical manufacturing; comparable as a specialist in novel chemistry routes for API production.

TypeBroad incumbent
Description

Snapdragon's parent company and a leading global small-molecule API CDMO — a broader incumbent whose full-service offering overlaps Snapdragon's niche while providing the platform within which Snapdragon operates.

TypeBroad incumbent
Description

One of the world's largest CDMOs, offering end-to-end API development and manufacturing including complex chemistry — a broad incumbent that competes for the same complex-API programs Snapdragon targets.

TypeBroad incumbent
Description

Global CRO/CDMO offering lab, CMC, and API manufacturing services; comparable to Snapdragon in chemistry services though with a much broader, integrated service portfolio.

TypeBroad incumbent
Description

Large-scale Chinese CDMO covering API process R&D and GMP manufacturing for complex small molecules — a broad incumbent competing directly in Snapdragon's specialty.

TypeDirect peer
Description

US-headquartered CDMO providing API development, complex formulation, and analytical services — a similarly-sized specialist directly comparable to Snapdragon's chemistry services focus.

TypeDirect peer
Description

Contract development and manufacturing organization with strong API and complex chemistry capabilities; directly comparable to Snapdragon in the small-molecule CDMO category.

TypeBroad incumbent
Description

Diversified life-sciences giant whose Patheon CDMO business offers large-scale API and finished-dose services; competes broadly for complex chemistry programs that Snapdragon targets.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks4 records

Each record includes

Headline, Details, Source

Key highlights5 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles3 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors3 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Snapdragon Chemistry

Contract Pharmaceutical Chemistry Servicessnapdragonchemistry.com

Snapdragon Chemistry is a Waltham, MA-based subsidiary of Cambrex that develops practical manufacturing solutions for challenging chemical transformations, serving the pharmaceutical discovery and manufacturing sector through specialized synthetic chemistry expertise.

What Snapdragon Chemistry does

Snapdragon Chemistry is a Waltham, Massachusetts-based chemistry technology company founded in 2014, operating as a subsidiary of Cambrex. The company focuses on developing practical manufacturing solutions for challenging chemical transformations, positioning itself in the pharmaceutical process chemistry and contract development space. Its core capability centers on synthetic chemistry expertise applied to pharmaceutical discovery and manufacturing, with the company maintaining a 51–100 employee footprint and an executive team led by CEO Matthew Bio, alongside a CSO (Eric Fang) and COO (Rick Lifsitz), with co-founder Sera Hwang among the founding team.

The company's documented external-facing product is the annual Snapdragon Prize for Innovation in Chemistry Technology, established in 2024 with a $50,000 unrestricted research grant awarded to leading academic researchers in synthetic chemistry whose work has potential to impact pharmaceutical discovery and manufacturing. The 2025 prize was awarded to Dr. Song Lin of Cornell University for work in electrosynthetic chemistry. Beyond the prize, the company has secured non-dilutive funding from DARPA ($1.5M, 2021), the National Science Foundation (~$225K, 2016), and the Massachusetts Life Sciences Center ($200K, 2017), indicating participation in government and translational research programs.

Business model specifics — pricing, customer mix, contract structure, and revenue mechanics — are not disclosed in available sources. Given the Cambrex parent, the implied model is likely a B2B services model serving pharmaceutical clients through Cambrex's broader commercial infrastructure, with Snapdragon functioning as a specialized process chemistry and innovation unit. Customer logos, segment composition, technology stack, and pricing are not publicly disclosed, representing a material evidence gap for any investor diligence.

Snapdragon Chemistry firmographics

Firmographics
Name
Snapdragon Chemistry
Website
https://snapdragonchemistry.com
Company type
Private
Founded year
2014
Operating status
Operating
Headcount range
51–100 employees
Short description
Snapdragon Chemistry is a Waltham, MA-based subsidiary of Cambrex that develops practical manufacturing solutions for challenging chemical transformations, serving the pharmaceutical discovery and manufacturing sector through specialized synthetic chemistry expertise.
Ownership category
akta.pro rank

Snapdragon Chemistry industry classification

Industry
Product category
Contract Pharmaceutical Chemistry Services
NAICS
Pharmaceutical and Medicine Manufacturing (32541), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Medicinal Chemicals & Botanical Products (2833)
akta.pro industry
PRIMARYHLAGAHAE
Chiral / Asymmetric Synthesis & Complex Chemistry Services
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAGAHAL
GMP Scale-Up, Tech Transfer & Process Validation (PPQ)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/API & Small-Molecule Development/Manufacturing Services
SECONDARYHLAIALAD
CMC & Pharmaceutical Development (Formulation/Process/Analytical Development)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • Contract pharmaceutical chemistry
  • Custom synthesis services
  • Chemical process development
  • API manufacturing solutions
  • Synthetic chemistry research

Where Snapdragon Chemistry is headquartered

Location

Headquarters

HQ city
Waltham
HQ country
United States
HQ region
North America

Markets served

Snapdragon Chemistry business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Infrastructure

Snapdragon Chemistry product offering

Product offering

Core offering

Snapdragon Chemistry develops practical manufacturing solutions for challenging chemical transformations, providing custom synthesis and process development services to pharmaceutical and biotech clients. The company focuses on solving difficult synthetic chemistry problems to enable scalable production of active pharmaceutical ingredients.

Product overview

Snapdragon Chemistry, a subsidiary of Cambrex, operates as a chemistry technology company. Based on the source data, the company appears to focus on pharmaceutical chemistry development and manufacturing, with its primary documented offering being the Snapdragon Prize for Innovation in Chemistry Technology—an annual award program established in 2024 that recognizes academic researchers in synthetic chemistry whose work advances pharmaceutical discovery and manufacturing.

Differentiator

Problem solved

Functional benefit

Products and services

  • Custom Synthesis Services

Companies that use Snapdragon Chemistry

Customer profile

Ideal customer profiles1 record

Snapdragon Chemistry technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Snapdragon Chemistry partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • CambrexcoreStrategic or Co-development Partner · 19 February 2026Snapdragon Chemistry is a subsidiary of Cambrex. Cambrex announced the 2025 Snapdragon Prize for Innovation in Chemistry Technology awarded to Dr. Song Lin from Cornell University. The prize recognizes academic research in synthetic chemistry that impacts pharmaceutical discovery and manufacturing.

Recent moves6 records

Expansion highlights2 records

Snapdragon Chemistry competitors and assessment

Company assessment

Direct peers

  • Asymchem: China-headquartered CDMO with deep capabilities in complex small-molecule chemistry, chiral synthesis, and API manufacturing — directly comparable to Snapdragon's challenging-transformations focus, with a much larger operational footprint.
  • Hovione: Privately-held specialist CDMO known for complex API development, particle engineering, and challenging chemistry — closely aligned with Snapdragon's positioning in difficult small-molecule manufacturing.
  • Codexis: Publicly-traded enzyme engineering company that develops biocatalytic and synthetic routes for pharmaceutical manufacturing; comparable as a specialist in novel chemistry routes for API production.
  • Alcami: US-headquartered CDMO providing API development, complex formulation, and analytical services — a similarly-sized specialist directly comparable to Snapdragon's chemistry services focus.
  • Curia (formerly AMRI): Contract development and manufacturing organization with strong API and complex chemistry capabilities; directly comparable to Snapdragon in the small-molecule CDMO category.

Broad incumbents

  • Cambrex: Snapdragon's parent company and a leading global small-molecule API CDMO — a broader incumbent whose full-service offering overlaps Snapdragon's niche while providing the platform within which Snapdragon operates.
  • Lonza: One of the world's largest CDMOs, offering end-to-end API development and manufacturing including complex chemistry — a broad incumbent that competes for the same complex-API programs Snapdragon targets.
  • Pharmaron: Global CRO/CDMO offering lab, CMC, and API manufacturing services; comparable to Snapdragon in chemistry services though with a much broader, integrated service portfolio.
  • WuXi STA (WuXi AppTec): Large-scale Chinese CDMO covering API process R&D and GMP manufacturing for complex small molecules — a broad incumbent competing directly in Snapdragon's specialty.
  • Thermo Fisher Scientific (Patheon CDMO): Diversified life-sciences giant whose Patheon CDMO business offers large-scale API and finished-dose services; competes broadly for complex chemistry programs that Snapdragon targets.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks4 records

Key highlights5 records

Customer concentration

Snapdragon Chemistry social profiles

Digital presence

Snapdragon Chemistry financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Snapdragon Chemistry leadership team

Management profile

Number of profiles

Profiles3 records

Snapdragon Chemistry funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Snapdragon Chemistry M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Snapdragon Chemistry

What does Snapdragon Chemistry do?

Snapdragon Chemistry develops practical manufacturing solutions for challenging chemical transformations, providing custom synthesis and process development services to pharmaceutical and biotech clients. The company focuses on solving difficult synthetic chemistry problems to enable scalable production of active pharmaceutical ingredients.

Is Snapdragon Chemistry a public or private company?

Snapdragon Chemistry is a private company. It is classified as corporate owned and is currently operating.

When was Snapdragon Chemistry founded?

Snapdragon Chemistry was founded in 2014. It employs 51 to 100 people.

Where is Snapdragon Chemistry based?

Snapdragon Chemistry is headquartered in Waltham, United States, in the North America region.

Who are Snapdragon Chemistry's main competitors?

Direct peers on record are Asymchem, Hovione, Codexis, Alcami and Curia (formerly AMRI). Broad incumbents are Cambrex, Lonza, Pharmaron, WuXi STA (WuXi AppTec) and Thermo Fisher Scientific (Patheon CDMO).

Does Snapdragon Chemistry have an API?

No public API is recorded for Snapdragon Chemistry.

What industry is Snapdragon Chemistry in?

Snapdragon Chemistry's product category is Contract Pharmaceutical Chemistry Services. Its primary akta.pro industry code is HLAGAHAE, Chiral / Asymmetric Synthesis & Complex Chemistry Services, with a secondary code of HLAGAHAL, GMP Scale-Up, Tech Transfer & Process Validation (PPQ). Its NAICS code is 32541 and its SIC code is 2833.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
PR NewswireCambrex, Snapdragon Chemistry et Q1 Scientific sont reconnus pour leur innovation et leur durabilité dans le secteur pharmaceutiqueCambrex and its subsidiaries have received multiple sustainability recognitions in the pharmaceutical sector, including Snapdragon Chemistry and NewAmsterdam Pharma jointly winning the American Chemical Society's Green Chemistry Challenge Award 2026 for developing an organocatalytic synthesis process for obicetrapib that reduces mass intensity by ~80%, shortens manufacturing cycle by ~70%, and cuts production costs by ~50%. Separately, Cambrex's Milan site earned EcoVadis Gold certification, ranking it among the top 5% of organizations for environmental, social, and ethical performance, and Cambrex subsidiary Q1 Scientific partnered with Flogas to source ~50% of its electricity from a wind farm in Ireland.FinanzNachrichten.deEQS-News: Cambrex, Snapdragon Chemistry und Q1 Scientific werden für Innovation und Nachhaltigkeit in der Pharmabranche ausgezeichnetCambrex announced that its subsidiary Snapdragon Chemistry, together with NewAmsterdam Pharma, received the American Chemical Society's Green Chemistry Challenge Award 2026 for developing a sustainable organocatalytic process to manufacture Obicetrapib, a drug candidate for treating dyslipidemia.PR NewswireCambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in PharmaCambrex announced that its subsidiary Snapdragon Chemistry, together with NewAmsterdam Pharma, received the American Chemical Society's 2026 Green Chemistry Challenge Award for developing a sustainable organocatalytic manufacturing process for obicetrapib. The process achieved an approximately 80% reduction in process mass intensity, 70% shorter manufacturing cycle time, and 50% lower manufacturing costs while eliminating aqueous waste generation. Separately, Cambrex's Milan facility earned the EcoVadis Gold rating, placing it in the top 5% of organizations evaluated, and Cambrex subsidiary Q1 Scientific entered a Corporate Power Purchase Agreement with Flogas to source renewable electricity covering approximately 50% of its Waterford site.PR NewswireCambrex, Snapdragon Chemistry und Q1 Scientific werden für Innovation und Nachhaltigkeit in der Pharmabranche ausgezeichnetCambrex subsidiary Snapdragon Chemistry, together with NewAmsterdam Pharma, was awarded the American Chemical Society's Green Chemistry Challenge Award 2026 for developing a sustainable organocatalytic process to manufacture the chiral tetrahydroquinoline core of Obicetrapib, a late-stage drug candidate for treating dyslipidemia. The new process achieved an approximately 80% reduction in mass intensity, eliminated aqueous waste generation, shortened production cycle times by roughly 70%, and cut manufacturing costs by approximately 50% compared with the prior method. Additionally, Cambrex's Milan facility received EcoVadis Gold certification (top 5% globally), and Q1 Scientific, another Cambrex group company, entered a corporate power purchase agreement with Flogas to source renewable wind electricity covering about 50% of its Waterford site demand.PR NewswireCambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in PharmaCambrex and its subsidiaries received multiple sustainability recognitions, including the American Chemical Society's 2026 Green Chemistry Challenge Award jointly awarded to Snapdragon Chemistry and NewAmsterdam Pharma for developing an organocatalytic manufacturing process for obicetrapib that reduced process mass intensity by approximately 80%, eliminated aqueous waste, shortened cycle time by approximately 70%, and lowered costs by approximately 50%. Cambrex's Milan facility also earned the EcoVadis Gold rating, placing it among the top 5% of organizations evaluated for environmental, social, and ethical performance, while Q1 Scientific partnered with Flogas to source renewable electricity from the Cronalaght Wind Farm covering approximately 50% of its Waterford site's electricity demand.PR Newswire APACCambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in PharmaCambrex, through its subsidiary Snapdragon Chemistry together with NewAmsterdam Pharma, has received the American Chemical Society's 2026 Green Chemistry Challenge Award for developing a sustainable organocatalytic process to manufacture obicetrapib, achieving an 80% reduction in process mass intensity, 70% shorter cycle time, and 50% lower costs. Cambrex's Milan facility also earned the EcoVadis Gold rating, placing it among the top 5% of organizations evaluated for environmental, social and ethical performance. Additionally, Q1 Scientific, another Cambrex company, partnered with Flogas to source renewable electricity from Cronalaght Wind Farm, covering approximately 50% of its Waterford site's electricity demand.BioSpaceCambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in PharmaCambrex's Snapdragon Chemistry and NewAmsterdam Pharma won the ACS 2026 Green Chemistry Challenge Award for a sustainable organocatalytic process making a chiral tetrahydroquinoline core for obicetrapib. The process cut process mass intensity by ~80%, eliminated aqueous waste, and shortened cycle time by ~70%. Cambrex's Milan facility also received an EcoVadis Gold rating.NewswireCambrex, Snapdragon Chemistry, and Q1 Scientific Recognized for Innovation and Sustainability in PharmaCambrex's Snapdragon Chemistry and NewAmsterdam Pharma won the American Chemical Society's 2026 Green Chemistry Challenge Award for a sustainable organocatalytic process making a chiral tetrahydroquinoline core for obicetrapib. The process cut process mass intensity by ~80%, eliminated aqueous waste, and lowered costs by ~50%. Q1 Scientific also partnered with Flogas to source renewable electricity from a wind farm.PR NewswireCambrex Announces Cornell Professor Song Lin as Recipient of the 2025 Snapdragon Prize for Innovation in Chemistry TechnologyCambrex and its subsidiary Snapdragon Chemistry announced Dr. Song Lin, Tisch University Professor at Cornell University, as the recipient of the 2025 Snapdragon Prize for Innovation in Chemistry Technology, which includes a $50,000 unrestricted research fund for his Lin Lab. Dr. Lin is being recognized for his pioneering work in electrosynthetic chemistry, which has advanced the application of electrochemistry in pharmaceutical development and manufacturing. The prize, established in 2024, annually honors one academic researcher whose work has the potential to significantly impact pharmaceutical discovery and manufacturing.